drugset / Trial / NCT01772719

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

NCT01772719

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.

Timeline

Start
2012-08
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Simvastatin Small molecule 80 mg Oral
Subject Zoledronic acid Other / unclassified 4 mg Intravenous

Indications